Previous 10 | Next 10 |
- BBP-398, an investigational SHP2 inhibitor, is a potentially optimal agent for use in combination therapies given its continuous, once-daily dosing in addition to synergistic activity with other agents to treat cancers driven by KRAS G12C mutations - The combination of investi...
- The conference will take place at the National Cancer Institute at Frederick, Maryland from October 17-19, 2022 - Presentation to include details from next-generation G12C dual inhibitor clinical candidate and characterization of advanced leads from the PI3Kα:RAS ...
The European Commission (EC) granted marketing authorization to BridgeBio Pharma ( NASDAQ: BBIO ) and Sentynl Therapeutics' Nulibry to treat patients with molybdenum cofactor deficiency (MoCD) Type A. Nulibry (fosdenopterin) for injection is the first therapy appr...
- The first and only treatment in Europe to treat patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival age of about four years. - European Commission (EC...
Summary Halvorsen's 13F portfolio value decreased from $24.74B to $21.86B this quarter. The number of positions increased from 56 to 82. Viking Global added McKesson, American International Group, and Intuit while decreasing T-Mobile US, General Electric, and Brookfield Asset Mana...
Summary Ascendis Pharma is now a commercial-stage company with a full pipeline and a revenue stream. There are multiple upcoming catalysts, including oncology data due by year end, which may validate the breadth of the platform. TransCon PTH has a large commercial opportunity....
PALO ALTO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team w...
Summary Today, we take a look at BridgeBio Pharma, whose stock had a large fall at the end of 2021 on some disappointing trial results. However, the company has several other late-stage candidates in development as well as collaboration deals with drug giants like Bristol Myers Sq...
Gainer: Kinnate Biopharma ( KNTE ) +5% . Kezar Life Sciences ( KZR ) +5% . BridgeBio Pharma ( BBIO ) +5% . Stronghold Digital Mining ( SDIG ) +3% . IDEAYA Biosciences ( IDYA ) +3% . Losers: Advanced Emissions Solutions ( ...
BridgeBio Pharma ( NASDAQ: BBIO ) said the first patient was dosed in its phase 1 trial of oral therapy BBP-671 being developed to treat conditions caused by coenzyme A (CoA) deficiencies. Coenzyme A plays a role in metabolism via synthesis and oxidation of fatty ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025 - Recent Type C interactions with U.S. Food and Drug Administration (FDA) focu...